A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
Status:
Completed
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to provide continued access to TMC278 in HIV-1 infected patients
who were randomized and treated with TMC278 in the Phase IIb or Phase III trials.